Osteoporosis is a prevalent metabolic bone disorder characterized by reduced bone mass and structural deterioration, leading to increased fracture risk. It predominantly affects postmenopausal women due to the sharp decline in estrogen levels, which accelerates bone resorption. Identifying biomarkers that can predict the development and progression of osteoporosis is critical for early diagnosis and targeted therapeutic interventions. Among the numerous candidate genes, the osteoprotegerin gene has emerged as a potential biomarker due to its pivotal role in regulating bone metabolism. Osteoprotegerin, a glycoprotein encoded by the TNFRSF11B gene, functions as a decoy receptor for the receptor activator of nuclear factor kappa-Β ligand. RANKL is a critical mediator of osteoclast differentiation and activation, promoting bone resorption.
HTML PDFShare this article
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report
